Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.55 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.46 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918173 | 1.00 | TYMP (0.55) | TYMPP2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL918537 | 0.95 | TYMP (0.55) | TYMPP2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL918538 | 0.95 | TYMP (0.55) | TYMPP2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL30396368 | 0.92 | TYMP (0.58) | TYMPP2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL30091055 | 0.92 | TYMP (0.58) | TYMPP2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL23650062 | 0.92 | TYMP (0.58) | TYMPP2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL6513309 | 0.92 | TYMP (0.58) | TYMPP2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL7708120 | 0.92 | TYMP (0.58) | TYMPP2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL6900160 | 0.90 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL6834984 | 0.90 | TYMP (0.56) | TYMPP2RY12P2RY2P2RY1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252919-B2 | 2′-hydroxy-protected ribonucleoside derivative and production method thereof | KANEKA CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | KANEKA CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258709-A1 | 2'-HYDROXYL-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND MANUFACTURING METHOD OF SAME | Kaneka Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | RNASEL, RNASEH1, NUDT1 | TYMP 183/4885P2RY12 3020/4885P2RY2 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.